Top

European Child & Adolescent Psychiatry

Published in:

01-01-2009 | ORIGINAL CONTRIBUTION

Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder

Authors: Fariba Arabgol, M.D., Leily Panaghi, M.D., Paria Hebrani, M.D.

Published in: European Child & Adolescent Psychiatry | Issue 1/2009

Abstract

Background and purpose

Attention deficit-hyperactivity disorder (ADHD) is a common psychiatric diagnosis among children and adolescents. This study has been conducted to evaluate the efficacy and tolerability of reboxetine in comparison with methylphenidate in treatment of children and adolescents with ADHD.

Methods

Thirty three children, 7–16 years of age, diagnosed with ADHD, participated in a 6-week, double-blind clinical trial with reboxetine (4–6 mg/d) and methylphenidate (20–50 mg/d) in two divided doses. The principal measure of the outcome was the Teacher and Parent ADHD Rating Scale. Patients were assessed by a child psychiatrist at baseline, 14, 28, and 42 days after the start of medication.

Results

No significant differences were observed between the two protocols on the Parent (P = 0.26) and Teacher (P = 0.97) ADHD Rating Scale scores and in treatment dropouts. A significant improvement in ADHD symptoms was observed over the 6 weeks of treatment for Parent ADHD Rating Scale (P < 0.001) and Teacher ADHD Rating Scale score in both groups (P < 0.001). The most common adverse effects reported with reboxetine were drowsiness and anorexia with mild to moderate severity.

Conclusions

The study revealed that reboxetine may be beneficial in treatment of ADHD. Further studies are required to clarify the potential therapeutic effects on comorbid depression and anxiety and adverse effect profile.

Akhondzadeh SH, Tvakolian R, Davari-Ashtiani R, Arabgol F, Amini H (2003) Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double-blind and randomized trial. Prog Neuro-Psychopharmacol Bio Psychiatry 27:841–845CrossRef

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn. Text revised (DSM-VI-TR). American Psychiatric Association. Washington

Banaschewski T, Roessener V, Dittman RW, Santsho PJ, Rothenberger A (2004) Non stimulant medications in the treatment of ADHD. In: Taylor E, Dopfner M, Sergeant J, Asherson PH, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Stenhausen H-CH, Zuddas A (2004) European clinical guideline for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):1/7–1/30

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, V.Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders, a systemic review and European treatment guideline. Eur Child Adolesc Psychiatry 15:476–495PubMedCrossRef

Biederman J, Spenser T, Wilentst T (2004) Evidence-based pharmacotherapy for attention deficit hyperactivity disorder. Int Neurophsychopharmacol 7:77–97CrossRef

Bock N, Quentin DJ, Hüther G, Moll GH, Banaschewski T, Rothenberger A (2005) Very early treatment with fluoxetine and reboxetine causing long lasting changes of the serotonin but not the noradrenaline transporter in the frontal cortex of rats. World J Biol Psychiatry 6:107–112PubMedCrossRef

Bymaster FP, Katner J, Nelson DL, et al (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder In: E- Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Barker KD, Feldman PD, Gelowitz DL (2006). Effects of long-term atomoxetine treatment for young children with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919–927

De Battista C, Schatzberg AF (2005) Other pharmacological and biological therapies. In: Sadock BJ, Sadock VA (eds) Comprehensive textbook of psychiatry, 8th edn, Lippincatt Williams & Wilkins, Baltimore, p 2997

Dupaul GJ (1991) Parent and teacher rating of ADHD symptoms: psychometric properties in a community based sample. J Clin Child Psychol 20:245–253CrossRef

10.

Edwards DM, Pellizoni C, Breuel HP, Beraridi A, Catelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M (1995) Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses. Linearity and plasma protein binding. Biopharm Drug Dispos 16:443–460PubMedCrossRef

11.

Gilberg C, Melander H, Knorring A (1997) Long term stimulant treatment of children with attention deficit hyperactivity disorder symptoms. Arch Gen Psychiatry 54:857–864

12.

Kehpe WA (2001) Treatment of attention deficit hyperactivity disorder in children. Ann pharmacother 35:1130–1134CrossRef

13.

Klein RG, Landa B (1988) Methylphenidate and growth in hyperactive children. Arch Gen Psychiatry 45:1127–1130PubMed

14.

Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Barker KD, Feldman PD, Gelowitz DL (2006) Effects of long-term atomoxetine treatment for young children with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919–927PubMedCrossRef

15.

Massino M (1997) Reboxetine: a review of antidepressant tolerability. J Psychopharm 11(Suppl 4):S33–S37

16.

Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD study group (2001) Atomoxetin in the treatment of children and adolescent with attention deficit hyperactivity disorder: a randomized placebo-controlled dose-response study. Pediatrics 108:E83PubMedCrossRef

17.

Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescent with attention deficit hyperactivity disorder: a randomized placebo-controlled study. Am J Psychiatry 159:1896–1901PubMedCrossRef

18.

Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optimal treatment for hyperactive conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 15:259–269PubMedCrossRef

19.

Otka JE, Mercadante MT, Scahill L, Leckman JF (2001) Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder [letter to the editor]. J Child Adolesc Psychopharmacol 11:203–204PubMedCrossRef

20.

Pataki C, Carlson G (1993) Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 32:1065–1082PubMedCrossRef

21.

Prince JB, Wilens TE, Biederman J (2000) A controlled study of nortriptyline in children and adolescent with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10:193–204PubMedCrossRef

22.

Klein RG, Abikoff H, Barkely RA, Campbell M, Leckman JF, Ryan ND, Solanto MV, Whalen CK (1994) Clinical trial in children and adolescents. In: Clinical evaluation of psychotherapic drugs: principles and guidelines. Edited by Prien RF, Rabinson DS. New York, Raven press, pp 501–546

23.

Ratner SH, Laor N, Bronstein Y, Weizman A,Toren P (2005) Six week open-label reboxetine treatment in children and adolescents with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 44:428–433PubMedCrossRef

24.

Sadock BJ, Sadock VA (2007) Kaplan and sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry, 10th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1206–1217

25.

Safer DJ (1997) Central stimulant treatment of childhood attention deficit hyperactivity disorder across the life cycle. CNS Drugs 7:264–272CrossRef

26.

Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffins S (1996) Pharmacotherapy of attention deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409–432PubMedCrossRef

27.

Spencer T, Biederman J, Wilens T (2004) Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin N Am 27:373–383CrossRef

28.

Taylor E, Dopfner M, Sergeant J, Asherson PH, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Stenhausen H-CH, Zuddas A (2004) European clinical guideline for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):1/7–1/30

29.

Tenreiro K (2001) Methylphenidate-placebo: a trial for attention deficit disorders. Int J Pharm Compd 5:21–22

30.

Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R (1999) Reboxetine, a unique selective NRI, prevents relapse and recurrence in long term treatment of major depressive disorder In: Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optimal treatment for hyperactive conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 15:259–269

31.

Weiss M, Weiss G (1996) Attention deficit hyperactivity disorder. In: Lewis M (eds) Child and adolescent psychiatry, 3rd edn. Williams and Wilkins, Baltimore, pp 645–670

32.

Wilens TE, Biederman J (1992) The stimulants. Psychiatr Clin N Am 90:191–222

Title: Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder
Authors: Fariba Arabgol, M.D.
Leily Panaghi, M.D.
Paria Hebrani, M.D.
Publication date: 01-01-2009
Publisher: D. Steinkopff-Verlag
Published in: European Child & Adolescent Psychiatry / Issue 1/2009
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-008-0705-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder

Abstract

Background and purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Using participatory design to develop structured training in child and adolescent psychiatry

Factors affecting nightmares in children: parents’ vs. children’s ratings

Treatment of oppositional defiant and conduct problems in young Norwegian children

Molecular genetic contribution to the developmental course of attention-deficit hyperactivity disorder

A randomised controlled trial into the effects of food on ADHD

Asperger syndrome